Showing 751-760 of 8973 results for "".
DermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://reachmd.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to privJournal Club: Dupilumab and Atopic March
https://reachmd.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-dupilumab-and-atopic-march/32405/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Peter Lio, MD, discuss recent research indicating a reduced risk of atopic march in pediatric atopic dermatitis patients on dupilumab.Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. ReducedMedical Dermatology Highlights
https://reachmd.com/programs/practical-dermatology/medical-dermatology-highlights/35889/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, summarizes the various medical dermatology sessions he presented at Music City SCALE 2025.Procedural Management for HS
https://reachmd.com/programs/practical-dermatology/procedural-management-for-hs/35891/Vivian Shi, MD, talks about procedural management for hidradenitis suppurativa and how to incorporate those procedures with medical management of the condition at Music City SCALE 2025.Novel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://reachmd.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.Dr. Anderson on New Tech That ‘Could be Revolutionary’ at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-anderson-on-new-tech-that-could-be-revolutionary-at-maui-derm/32921/In-vivo microscopy that will change how dermatologists practice and potentially revolutionary drug delivery systems were among the technologies highlighted by R. Rox Anderson, MD, PhD, during “Innovation in Dermatology 2025: A Look Into the Future of Dermatology” at the Maui Derm Hawaii 2025 meetingDr. Eichenfield Urges Caution for Steroid-Phobia at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-eichenfield-urges-caution-for-steroid-phobia-at-maui-derm/32919/In addition to the various clinical skin conditions that pediatric patients present with, dermatologists now must understand how to deal with steroid-phobia, according to Lawrence Eichenfield, MD.Maui Derm Panel: GLP-1 Agonists Can Help Psoriasis Patients
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/maui-derm-panel-glp-1-agonists-can-help-psoriasis-patients/32917/Only 11% of Maui Derm 2025 audience members polled said they were comfortable prescribing weight-loss drugs, and 49% said they were not at all—but they should be, according to the presenters of “Psoriasis Update 2025” at the conference in Maui, Hawaii.Various Skin Cancer Therapies Covered at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/various-skin-cancer-therapies-covered-at-maui-derm/32915/With a theme of understanding the various options available for treatment of skin cancers and selecting the correct ones for each case, George Martin, MD, Ted Rosen, MD, and Emily Ruiz, MD, MPH, presented “Cutaneous Oncology Update 2025” at the Maui Derm Hawaii 2025 meeting in Maui, Hawaii.Leading Dermatologists Summarize Maui Derm Presentations
https://practicaldermatology.com/series/dermwire-tv/leading-dermatologists-summarize-maui-derm-presentations/32839/In this week's DermwireTV, top thought leaders provide a summary of their presentations at Maui Derm; a new analysis examines a link between hidradenitis suppurativa genetics and coronary artery disease risk; and the president of Castle Biosciences joins us for this week's C-Suite Chats f